[go: up one dir, main page]

FR11C0020I1 - - Google Patents

Info

Publication number
FR11C0020I1
FR11C0020I1 FR11C0020C FR11C0020I1 FR 11C0020 I1 FR11C0020 I1 FR 11C0020I1 FR 11C0020 C FR11C0020 C FR 11C0020C FR 11C0020 I1 FR11C0020 I1 FR 11C0020I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27301396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0020(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR11C0020I1 publication Critical patent/FR11C0020I1/fr
Application granted granted Critical
Publication of FR11C0020I2 publication Critical patent/FR11C0020I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
FR11C0020C 1996-12-26 2011-06-21 Difluoroprostaglandin derivatives and their application Active FR11C0020I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34861496 1996-12-26
JP7405497 1997-03-26
JP17247797 1997-06-27

Publications (2)

Publication Number Publication Date
FR11C0020I1 true FR11C0020I1 (en) 2011-07-29
FR11C0020I2 FR11C0020I2 (en) 2012-03-16

Family

ID=27301396

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0020C Active FR11C0020I2 (en) 1996-12-26 2011-06-21 Difluoroprostaglandin derivatives and their application

Country Status (16)

Country Link
US (2) US5886035A (en)
EP (1) EP0850926B1 (en)
JP (2) JP3480549B2 (en)
KR (1) KR100526282B1 (en)
CN (1) CN1108289C (en)
AT (1) ATE225770T1 (en)
CA (1) CA2225761C (en)
DE (2) DE69716226T2 (en)
DK (1) DK0850926T3 (en)
ES (1) ES2187719T3 (en)
FR (1) FR11C0020I2 (en)
LU (1) LU91943I2 (en)
NL (1) NL300407I2 (en)
NO (2) NO317060B1 (en)
PT (1) PT850926E (en)
TW (1) TW536534B (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012175A1 (en) * 1996-09-17 1998-03-26 Asahi Glass Company Ltd. Fluorinated prostaglandin derivatives and medicines
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
IL134241A (en) 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
WO2001055102A1 (en) * 2000-01-28 2001-08-02 Asahi Glass Company, Limited Novel difluoroprostaglandin derivative
AU2001286210A1 (en) * 2000-09-13 2002-03-26 Asahi Glass Company, Limited Eye drops
US20050228048A1 (en) * 2002-08-23 2005-10-13 Santen Pharmaceutical Co., Ltd. Stable eye drops containing latanoprost as the active ingredient
CA2498233C (en) 2002-09-09 2012-08-14 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US20060199863A1 (en) * 2003-07-31 2006-09-07 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
CA2548412C (en) * 2003-12-08 2011-04-19 Qualcomm Incorporated High data rate interface with improved link synchronization
RU2429849C2 (en) * 2004-12-09 2011-09-27 Сантен Фармасьютикал Ко., Лтд Product containing prostaglandin having fluorine atom in molecule
JP4753178B2 (en) * 2004-12-24 2011-08-24 参天製薬株式会社 Products containing prostaglandin F2α derivatives
CA2602573C (en) * 2005-03-31 2013-10-08 Asahi Glass Co Ltd Protective agent for retinal neuronal cell containing prostaglandin f2 .alpha. derivative as active ingredient
JP5100025B2 (en) * 2005-03-31 2012-12-19 旭硝子株式会社 Retinal nerve cell protective agent containing prostaglandin F2α derivative as an active ingredient
EP1870099A4 (en) 2005-04-13 2008-07-16 Ube Industries PROTECTIVE AGENT FOR RETINAL NEURAL CELL COMPRISING AN INDAZOLE DERIVATIVE AS ACTIVE INGREDIENT
CA2613010A1 (en) * 2005-06-29 2007-01-04 Pfizer Inc. Fluoroprostaglandins nitroderivatives
EP2735566A1 (en) * 2006-02-07 2014-05-28 R-Tech Ueno, Ltd. Method for preparing prostaglandin derivative
US7666912B2 (en) * 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
FR2918891B1 (en) * 2007-07-20 2009-09-25 Thea Sa Lab OPHTHALMIC SOLUTION BASED ON PROSTAGLANDINS WITHOUT PRESERVATIVE
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
CN102143753B (en) * 2008-09-04 2013-07-03 参天制药株式会社 Hair growth promoter containing 15,15-difluoroprostaglandin F2α derivative as an active ingredient
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
BR112013002584A2 (en) 2010-08-02 2016-06-07 Pharma Patent Holding Inc makeup, hair improvement kit process
CA2866067C (en) 2011-01-19 2015-04-21 Topokine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
TW202344254A (en) 2011-02-04 2023-11-16 日商興和股份有限公司 Medicines for the prevention or treatment of glaucoma or ocular hypertension
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
EP2812314A4 (en) * 2012-02-07 2015-08-19 Reddys Lab Ltd Dr Amine salts of prostaglandin analogs
CA2874288A1 (en) 2012-05-30 2013-12-05 Asahi Glass Company, Limited Composition for hair growth
WO2014081941A1 (en) 2012-11-21 2014-05-30 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
NO2753788T3 (en) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
CN103570549B (en) * 2013-10-11 2016-01-27 天泽恩源（天津）制药有限公司 A kind of method of synthesizing tafluprost
CN103804195B (en) * 2014-01-26 2016-06-15 天泽恩源（天津）制药有限公司 A kind of method synthesizing tafluprost
CN103819436A (en) * 2014-02-21 2014-05-28 天泽恩源（天津）医药技术有限公司 Crystal form of (3aR,4R,5R,6aS)-4-((E)-3,3-difluoro-4-phenoxylbutyl-1-alkyl-1-yl)-2-oxohexahydro-2H-cyclopentane[b]furan-5-benzoate, and preparation method of corresponding crystals thereof
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
KR20160116402A (en) 2015-03-30 2016-10-10 연성정밀화학(주) Process for Preparing Tafluprost
EA037327B1 (en) 2015-09-22 2021-03-12 Грейбуг Вижн, Инк. Compounds and compositions for the treatment of ocular disorders
CN107226790A (en) * 2016-03-25 2017-10-03 苏州朗科生物技术有限公司 A kind of preparation method and midbody compound of high-purity tafluprost and its similar compound
GR1009040B (en) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Preservative free pharmaceutical ophthalmic compositions
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
CN108299192A (en) * 2017-01-10 2018-07-20 江苏恒瑞医药股份有限公司 A kind of metal salt compound crystal form and preparation method thereof of tafluprost acid
CN106986766B (en) * 2017-05-08 2021-01-12 扬子江药业集团有限公司 Preparation method of tafluprost
CN112457277B (en) * 2020-12-16 2022-06-28 西安国康瑞金制药有限公司 Preparation method of tafluprost
CN115448840A (en) * 2021-01-27 2022-12-09 Ａｇｃ株式会社 Purification method of tafluprost
CN112832150B (en) * 2021-01-27 2022-06-24 中交第三公路工程局有限公司 A vertical chisel device for culvert passages and other vertical surfaces
CN116120268A (en) * 2023-03-06 2023-05-16 南京华威医药科技集团有限公司 A kind of tafluprost intermediate impurity and preparation method thereof
CN116425707A (en) * 2023-03-31 2023-07-14 南京华威医药科技集团有限公司 A kind of tafluprost intermediate isomer impurity and preparation method thereof
CN117024324A (en) * 2023-08-03 2023-11-10 南京华威医药科技集团有限公司 Preparation method of tafluprost enantiomer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH0770054A (en) * 1993-08-30 1995-03-14 R Tec Ueno:Kk Biological antagonist and disease-treating preparation
WO1998012175A1 (en) * 1996-09-17 1998-03-26 Asahi Glass Company Ltd. Fluorinated prostaglandin derivatives and medicines
ATE202557T1 (en) * 1996-11-12 2001-07-15 Alcon Lab Inc 15-FLUORO-PROSTAGLANDINS AS AN EYE PRESSURE-LOWERING AGENT

Also Published As

Publication number Publication date
ATE225770T1 (en) 2002-10-15
CA2225761C (en) 2009-04-21
EP0850926B1 (en) 2002-10-09
US5886035A (en) 1999-03-23
DE69716226T2 (en) 2003-06-05
US5985920A (en) 1999-11-16
NL300407I1 (en) 2009-11-02
CN1108289C (en) 2003-05-14
PT850926E (en) 2003-02-28
JPH1171344A (en) 1999-03-16
LU91943I2 (en) 2012-04-16
JP3994074B2 (en) 2007-10-17
FR11C0020I2 (en) 2012-03-16
CA2225761A1 (en) 1998-06-26
ES2187719T3 (en) 2003-06-16
CN1187486A (en) 1998-07-15
TW536534B (en) 2003-06-11
NL300407I2 (en) 2010-03-01
EP0850926A3 (en) 1999-06-16
DE69716226D1 (en) 2002-11-14
JP2004002462A (en) 2004-01-08
EP0850926A2 (en) 1998-07-01
NO317060B1 (en) 2004-08-02
NO2009006I1 (en) 2009-03-16
KR19980064718A (en) 1998-10-07
DK0850926T3 (en) 2003-02-17
NO976085D0 (en) 1997-12-23
NO976085L (en) 1998-06-29
KR100526282B1 (en) 2006-05-17
NO2009006I2 (en) 2012-03-05
JP3480549B2 (en) 2003-12-22
DE122008000050I2 (en) 2011-06-16
DE122008000050I1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
AR026659A2 (en)
BRPI9713914B8 (en)
BR7600721U (en)
BR7601346U (en)
BR9603859A (en)
CN3039060S (en)
CN3039213S (en)
CN3040024S (en)
CN3040367S (en)
CN3040543S (en)
CN3040550S (en)
CN3040805S (en)
CN3041115S (en)
CN3041207S (en)
CN3041374S (en)
CN3041383S (en)
CN3042193S (en)
CN3042289S (en)
CN3042424S (en)
CN3042589S (en)
CN3043305S (en)
CN3043413S (en)
CN3043414S (en)
CN3043415S (en)
CN3043416S (en)